The relative risks were @ ( @ % confidence interval -LSB- CI -RSB- @-@ @ ; p = @ ) for gadolinium-enhancing lesions ( the primary endpoint ) , @ ( @ % CI @-@ @ ; p = @ ) for new and enlarging T@-hyperintense lesions , and @ ( @ % CI @-@ @ ; p = @ ) for new T@-hypointense lesions .